الفهرس 
ACUTE LYMPHOBLASTIC LEUKEMIAOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
The incidence of severe fungal infections in
immunocompromised patients has increased dramatically
over the past 20 years. In neutropenic patients, these infections
are a major cause of morbidity and mortality. Between 20% to
40% of mycoses in patients with hematological malignancies
are disseminated and more than 70% of these are fatal.
Candidiasis and Aspergillosis are the most common fungal
infections in patients receiving immunosuppressive therapy
In order to study Impact of fungal infection on the
continuity of chemotherapy and disease outcome during
induction and consolidation therapy of childhood acute
lymphoblastic leukemia, we retrieved the archived clinical &
biological & laboratory data of 96 patient, consisting all
patients diagnosed with ALL during the time period between
January 2012 till December 2012 according to St. Jude’s total
XV protocol for low risk, standard risk /high risk.
Out of the 96 cases who diagnosed Acute ymphoblastic
leukemia, the incidence of probable fungal infection detected is
19/96 (19.8%) cases. Out of 19 cases had probable fungal infection
12/19 (63.2%) cases were low risk, 6/19 (31.6%) cases were
standard risk, 1/19 (5.3%) cases were High risk.
Out of 19 cases who diagnosed acute lymphoblastic
leukemia with probable fungal infection, 7/19(36.80%) cases had delay of chemotherapy. Out of 77 cases who diagnosed
Acute lymphoblastic leukemia with no probable fungal
infection detected, 4/77 (5.20%) cases had delay of
chemotherapy.
Out of 19 cases who diagnosed acute lymphoblastic
leukemia with probable fungal infection, 3/19 (15.80%) cases
died. Regarding state of their diseases, out of 19cases probable
fungal infection, 18/19 (94.7%) were in (CR) complete
remission, while 1/19 cases (5.3%) were not in remission (not
in CR).
Fungal infection is one of the major problems during
induction and consolidation of acute lymphoblastic leukemia
patients, affect the outcome & continuity of chemotherapy.